Clinical Trial

The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer

Active, Not Recruiting Phase 3

Summary

This trial aims to directly compare a reduced radiation dose to the standard of care in HPVOPC for non-inferiority, thus allowing for direct comparison of outcomes between the two groups. The study hypothesis is that LRC and PFS at 3 years for reduced dose CRT are non-inferior to standard dose CRT.

Protocol Amendment History 17 amendments

This ClinicalTrials.gov record has been amended 17 times since 2012-10-12; most recent amendment 2026-03-27.

Status change: Recruiting → Active, Not Recruiting 2017-03-21

Trial Details

NCT Number	NCT01706939
Lead Sponsor	Icahn School of Medicine at Mount Sinai Collaborators: Biodesign Institute, Arizona State University
Conditions	Squamous Cell Carcinomas
Enrollment	23 participants
Start Date	2012-09-01
Primary Completion	2020-04-01 (estimated)
Study Completion	2035-05-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-09